![]() It is an in vitro alternative to the traditional hybridoma-based technology for creating monoclonal antibodies. However, the main disadvantage with this technology is the difficulty of producing large quantities of stable human monoclonal antibodies, due to the absence of suitable myeloma cell lines.Ī recombinant antibody is a synthetic antibody or antibody fragment that is generated by recombinant DNA technology. If intended for therapeutic use, the antibody must undergo humanization, wherein parts of the protein sequence - usually the constant regions - are replaced with the human equivalent otherwise, it may elicit an unintended immune response in humans. Also, hybridomas are sometimes difficult and expensive to maintain in culture. More than 99% of the cells do not survive the fusion process, thus reducing the range of useful antibodies that can be produced against an antigen. Alternatively, monoclonal antibodies can be produced in vivo by injecting hybridoma cells into the peritoneal cavity of an animal and harvesting antibodies from the resulting fluid (ascites).Īlthough hybridoma antibody production is a well-established method of producing antibody, there are several drawbacks.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |